On October 29, the **FDA authorized** the Pfizer vaccine for children ages 5 to 11.

On November 2, the **CDC formally recommended** the Pfizer vaccine for children ages 5 to 11.

On November 19, **Health Canada authorized** the use of the Pfizer vaccine for children ages 5 to 11.

For this age group, the vaccine is to be administered in a **two-dose regimen of 10-µg doses given 21 days apart**.

Data from a Phase 2/3 randomized, controlled trial that included ~4,500 children ages 5 to 11 showed a favorable safety profile and **high vaccine efficacy of 90.7%**.

The kid-sized 10-µg dose — just one-third of the amount given to teens and adults — was carefully selected as the **optimal dose based on safety, tolerability and immunogenicity data**.

Long-term safety of COVID-19 vaccine in participants 5 to 11 years of age will be studied in 5 post-authorization safety studies, **including a 5-year follow-up study** to evaluate risks of myocarditis/pericarditis.

The Canadian government is expecting 2.9 million child-sized doses of the vaccine, enough for every child to get their first dose.

**References**